Page 410 - Binder2

hybrid: where biology and code co-create therapies, where
gene expression is tuned like software, and where every
leaf is part of a data stream.

If edible biologics represent the next chapter in drug
development, then AI is the architect writing it.

Why AI Is Essential to Plant-Based Drug
Development

Biologics are some of the most complex drugs in existence.
They’re not small molecules that can be synthesized with a
few chemical steps—they’re large, delicate proteins that
must:

• Fold correctly to preserve their active sites.
• Carry the right glycosylation patterns, which
affect their stability, immunogenicity, and efficacy.
• Achieve therapeutic yield within the plant system,
or risk becoming economically unviable.
• Pass consistency tests across multiple production
runs and locations.

In traditional biomanufacturing, these variables are
controlled inside steel bioreactors, where conditions can be
kept narrowly uniform.

But in plants—living, breathing, photosynthesizing
systems—these conditions are dynamic. Light levels
change. Temperatures shift. Water quality varies. No two
leaves are ever exactly alike.

To meet the standards of pharmaceutical production in such
an environment, you need more than agronomy.

408